Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Cited by (1,002)

Items 401–500 of 1,002

1. Hospital bed occupancy rate is an independent risk factor for COVID-19 inpatient mortality: a pandemic epicentre cohort study
   Francesco Castagna, Xiaonan Xue, Omar Saeed, Rachna Kataria, Yoram A. Puius, Snehal R. Patel, Mario Jorge Garcia, Andrew D. Racine, Daniel B. Sims, Ulrich P. Jorde · 2022 · BMJ Open
2. Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types
   Matthew C. Pahl, Carole Le Coz, Chun Su, Prabhat Kumar Sharma, Rajan M. Thomas, James A. Pippin, Emylette Cruz Cabrera, Matthew E. Johnson, Michelle E. Leonard, Sumei Lu et al. · 2022 · Genome biology
3. SARS-CoV-2–Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study
   Mai-Chi Trieu, Amit Bansal, Anders Madsen, Fan Zhou, Marianne Sævik, Juha Vahokoski, Karl Albert Brokstad, Florian Krammer, Camilla Tøndel, Kristin Greve-Isdahl Mohn et al. · 2020 · The Journal of Infectious Diseases
4. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice
   Eakachai Prompetchara, Chutitorn Ketloy, Kittipan Tharakhet, Papatsara Kaewpang, Supranee Buranapraditkun, Teerasit Techawiwattanaboon, Suwitra Sathean-anan-kun, Patrawadee Pitakpolrat, Supaporn Watcharaplueksadee, Supaporn Phumiamorn et al. · 2021 · PLoS ONE
5. A Single-Cell Atlas of Lymphocyte Adaptive Immune Repertoires and Transcriptomes Reveals Age-Related Differences in Convalescent COVID-19 Patients
   Florian Bieberich, Rodrigo Vazquez-Lombardi, A. Yermanos, Roy A. Ehling, Derek M. Mason, Bastian Wagner, Edo Kapetanovic, Raphaël B. Di Roberto, Cédric R. Weber, M. Savic et al. · 2021 · bioRxiv
6. Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection
   Karolin I. Wagner, Laura Marlene Mateyka, Sebastian Jarosch, Vincent Grass, Simone Weber, Kilian Schober, Monika Hammel, Teresa Burrell, Behnam Naderi Kalali, Holger Poppert et al. · 2021 · Cell Reports
7. Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status
   Esther Dawen Yu, Eric W. Wang, Emily Garrigan, Benjamin Goodwin, Aaron Sutherland, Alison Tarke, James Chang, Rosa Isela Gálvez, José Mateus, Sydney I. Ramirez et al. · 2022 · Cell Host & Microbe
8. Comparison of Lung-Homing Receptor Expression and Activation Profiles on NK Cell and T Cell Subsets in COVID-19 and Influenza
   Demi Brownlie, Inga Rødahl, Renata Varnaitė, Hilmir Ásgeirsson, Hedvig Glans, Sara Falck‐Jones, Sindhu Vangeti, Marcus Buggert, Hans‐Gustaf Ljunggren, Jakob Michaëlsson et al. · 2022 · Frontiers in Immunology
9. Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines
   Manish K. Dhawan, Ali Ahmed Rabaan, Mahmoud M. Fawarah, Souad A. Almuthree, Roua Abdullah Alsubki, Amal H. Alfaraj, Mutaib M. Mashraqi, Saleh Alshamrani, Wesam A. Abduljabbar, Ameen S. S. Alwashmi et al. · 2023 · Vaccines
10. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
    Patrick Harrington, Hugues de Lavallade, Katie J. Doores, Amy O’Reilly, Jeffrey Seow, Carl Graham, Thomas Lechmere, Deepti H. Radia, Richard James Dillon, Yogita Shanmugharaj et al. · 2021 · Leukemia
11. SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
    John Tyler Sandberg, Renata Varnaitė, Wanda Christ, Puran Chen, Jagadeeswara Rao Muvva, Kimia T. Maleki, Marina García, Majda Dzidic, Elin Folkesson, Magdalena Skagerberg et al. · 2021 · Clinical & Translational Immunology
12. SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron
    Alessio Mazzoni, Anna Vanni, Michele Spinicci, Manuela Capone, Giulia Lamacchia, Lorenzo Salvati, Marco Coppi, Alberto Antonelli, Alberto Carnasciali, Parham Farahvachi et al. · 2022 · Frontiers in Immunology
13. Universality in COVID-19 spread in view of the Gompertz function
    Akira Ohnishi A, Yusuke Namekawa, Tokuro Fukui · 2020 · Progress of Theoretical and Experimental Physics
14. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations
    Raffaella Greco, Tobias Alexander, Joachim Burman, Nicoletta Del Papa, Jeska de Vries‐Bouwstra, Dominique Farge, Jörg C. Henes, Majid A. Kazmi, Кирилл Игоревич Киргизов, Paolo Antonio Muraro et al. · 2021 · Bone Marrow Transplantation
15. SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
    Carolina Garrido, Alan Dale Curtis, Maria L. Dennis, Sachi Pathak, Hongmei Gao, David C. Montefiori, Mark A. Tomai, Christopher B. Fox, Pamela A. Kozlowski, Trevor Scobey et al. · 2021 · Science Immunology
16. SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single center study
    Michael N Brant-Zawadzki, Deborah Fridman, Philip A. Robinson, Matthew Zahn, Clayton Chau, Randy German, Marcus Breit, Jason R. Bock, Junko Hara · 2020 · PLoS ONE
17. Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs
    Abed Agbarya, Ina Sarel, Tomer Ziv‐Baran, Sivan Agranat, Orna Schwartz, Ayelet Shai, Sharon Nordheimer, Shlomit Fenig, Yelena Shechtman, Ella Kozlener et al. · 2021 · Cancers
18. TREM-2 is a sensor and activator of T cell response in SARS-CoV-2 infection
    Yongjian Wu, Manni Wang, Huan Yin, Siqi Ming, Xingyu Li, Guanmin Jiang, Ye Liu, Pei‐Hui Wang, Guangde Zhou, Lei Liu et al. · 2021 · Science Advances
19. T cell perturbations persist for at least 6 months following hospitalization for COVID-19
    Melissa Govender, Francis R. Hopkins, Robin Göransson, Cecilia Svanberg, Esaki Muthu Shankar, Maria Hjorth, Åsa Nilsdotter‐Augustinsson, Johanna Sjöwall, Sofia N. Nyström, Marie Larsson · 2022 · Frontiers in Immunology
20. Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors
    Daichao Wu, Alexander V. Kolesnikov, Rui Ming Yin, Johnathan D. Guest, Ragul Gowthaman, Anton Shmelev, Yana V. Serdyuk, Dmitry Vladimirovich Dianov, Grigory Aleksandrovich Efimov, Brian G. Pierce et al. · 2022 · Nature Communications
21. Role of genetic variants and host polymorphisms on COVID‐19: From viral entrance mechanisms to immunological reactions
    Abolfazl Adli, Mandana Rahimi, Reza Khodaie, Niloofar Hashemzaei, Sayed Mostafa Hosseini · 2022 · Journal of Medical Virology
22. Peculiarities of the T Cell Immune Response in COVID-19
    Dmitry Anatolievich Kudlay, И.А. Кофиади, Musa Rakhimovich Khaitov · 2022 · Vaccines
23. Humoral Response Dynamics Following Infection with SARS-CoV-2
    Louis Grandjean, Anja Saso, Arturo Torres Ortiz, Tanya Lam, James Hatcher, Rosie Thistlethwayte, Mark Harris, Timothy Best, Marina Johnson, Helen R. Wagstaffe et al. · 2020 · medRxiv
24. Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines
    Yexin Yang, Akiko Iwasaki · 2021 · Current HIV/AIDS Reports
25. Autoimmune Encephalitis in COVID-19 Infection: Our Experience and Systematic Review of the Literature
    Adina Stoian, Mircea Stoian, Zoltán Bajkó, Smaranda Maier, Sebastian Razvan Andone, Roxana Adriana Cioflinc, Anca Moțățăianu, Laura Bărcuţean, Rodica Bălașa · 2022 · Biomedicines
26. SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
    Curtis Cai, Yu Gao, Sarah Adamo, Olga Rivera‐Ballesteros, Lotta Hansson, Anders Österborg, Peter Bergman, Johan K. Sandberg, Hans‐Gustaf Ljunggren, Niklas K. Björkström et al. · 2023 · Science Immunology
27. Identification of soluble biomarkers that associate with distinct manifestations of long COVID
    Yu Gao, Curtis Cai, Sarah Adamo, Elsa Biteus, Habiba Kamal, Lena Dager, Kelly L. Miners, Sian Llewellyn‐Lacey, Kristin Ladell, Pragati S. Amratia et al. · 2025 · Nature Immunology
28. Use of machine learning to identify a T cell response to SARS-CoV-2
    M. Saad Shoukat, Andrew D. Foers, Stephen Woodmansey, Shelley C. Evans, Anna Fowler, Elizabeth J. Soilleux · 2021 · Cell Reports Medicine
29. Immunotherapy use outside clinical trial populations: never say never?
    Karolina Rzeniewicz, James Larkin, Alexander Maxwell Menzies, Samra Turajlic · 2021 · Annals of Oncology
30. Mucosal-associated invariant T cell responses differ by sex in COVID-19
    Yu Chen, Sejiro Littleton, Nicholas S. Giroux, Rose Mathew, Shengli Ding, Joan Kalnitsky, Yuchen Yang, Elizabeth Petzold, Hong A. Chung, Grecia O. Rivera et al. · 2021 · Med
31. Blood RNA signature RISK4LEP predicts leprosy years before clinical onset
    Maria Tió‐Coma, Szymon M. Kiełbasa, Susan J. F. van den Eeden, Hailiang Mei, Johan Chandra Roy, Jacco Wallinga, Marufa Khatun, Sontosh Soren, Abu Sufian Chowdhury, Khorshed Alam et al. · 2021 · EBioMedicine
32. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice
    Adrian Rice, Mohit S. Verma, Annie Shin, Lise Zakin, Peter A. Sieling, Shiho Tanaka, Joseph P. Balint, Kyle Dinkins, Helty Adisetiyo, Brett Morimoto et al. · 2021 · Scientific Reports
33. Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells
    Margaret Kruse, Chris Dark, Megan Aspden, Daniel Cochrane, Rick Competiello, Maya Peltz, Luis Torres, Peter Wrighton-Smith, Magdalena Dudek · 2021 · International Journal of Infectious Diseases
34. Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR
    Megan Catherine Schwarz, Denis Torre, Daniel Lozano‐Ojalvo, Anthony Tanoto Tan, Tommaso Tabaglio, Slim Mzoughi, Rodrigo Sánchez-Tarjuelo, Nina Le Bert, Joey Ming Er Lim, Sandra Hatem et al. · 2022 · Nature Biotechnology
35. Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics
    Vijay Kumar · 2020 · International Immunopharmacology
36. Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
    Lisa Blixt, Gordana Bogdanović, Marcus Buggert, Yu Gao, Sophia Hober, Katie Healy, Hemming Johansson, Christian Kjellander, Sára Mravinacová, Sandra Muschiol et al. · 2021 · Leukemia
37. Durability of SARS-CoV-2–Specific T-Cell Responses at 12 Months Postinfection
    Zhongyan Lu, Eric D. Laing, Jarina Pena DaMata, Katherine Pohida, Marana S Tso, Emily C Samuels, Nusrat J Epsi, Batsukh Dorjbal, Camille M. Lake, Stephanie A Richard et al. · 2021 · The Journal of Infectious Diseases
38. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
    Mammen P. Mammen, Pablo Tebas, Joseph T. Agnes, Mary Giffear, Kimberly Ann Kraynyak, Elliott Blackwood, Dinah H. Amante, Emma L. Reuschel, Mansi Purwar, Aaron Christensen-Quick et al. · 2021 · medRxiv
39. T cell and antibody responses to SARS-CoV-2: Experience from a French transplantation and hemodialysis center during the COVID-19 pandemic
    Sophie Candon, Dominique Guerrot, Laurent Drouot, Mathilde Lemoine, Ludivine Lebourg, Mélanie Hanoy, Olivier Boyer, Dominique Bertrand · 2020 · American Journal of Transplantation
40. Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
    Lutz Achtnichts, Barbara Jakopp, Michael Oberle, Krassen Nedeltchev, Christoph Andreas Fux, Johann Sellner, Oliver Findling · 2021 · Vaccines
41. Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants
    Saskia Meyer, Isaac Blaas, Ravi Chand Bollineni, Marina Delić-Šarac, Trung The Tran, Cathrine F. Knetter, Ke‐Zheng Dai, Torfinn Støve Madssen, John Torgils Vaage, Alice Gustavsen et al. · 2023 · Cell Reports
42. Robust mucosal SARS-CoV-2-specific T cells effectively combat COVID-19 and establish polyfunctional resident memory in patient lungs
    Airu Zhu, Zhao Chen, Qihong Yan, Mei Jiang, Xuesong Liu, Zhengtu Li, Na Li, Chunli Tang, Wenhua Jian, Jiangping He et al. · 2025 · Nature Immunology
43. Immune memory in convalescent patients with asymptomatic or mild COVID-19
    Quanxin Long, Yanjun Jia, Xin Wang, Haijun Deng, Xiaoxia Cao, Jun Yuan, Liang Fang, Xu-Rong Cheng, Chao Luo, An-Ran He et al. · 2021 · Cell Discovery
44. Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
    Anisha Misra, Elitza S. Theel · 2022 · Journal of Clinical Microbiology
45. SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells
    Cilia R. Pothast, Romy C. Dijkland, Melissa Thaler, Renate S. Hagedoorn, Michel G.D. Kester, Anne K. Wouters, Pieter Sicco Hiemstra, Martijn J. van Hemert, Stéphanie Gras, J.H. Frederik Falkenburg et al. · 2022 · eLife
46. T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID
    Lavanya Visvabharathy, Barbara Ann Hanson, Zachary S. Orban, Patrick H. Lim, Nicole M. Palacio, Millenia Jimenez, Jeffrey R. Clark, Edith L. Graham, Eric Michael Liotta, George Tachas et al. · 2021 · medRxiv
47. Inflammatory profiles and clinical features of coronavirus 2019 survivors 3 months after discharge in Wuhan, China.
    Zhou, Mei, Yin, Zhengrong, Xu, Juanjuan, Wang, Sufei, Liao, Tingting, Wang, Kai, Li, Yumei, Yang, Fan, Wang, Zhen, Yang, Guanghai et al. · 2021 · The Journal of Infectious Diseases
48. Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19
    Alessandra Soares Schanoski, Natalie Sauerwald, Carl W. Goforth, Sivakumar Periasamy, Dawn L. Weir, Stephen E. Lizewski, Rhonda A. Lizewski, Yongchao Ge, Natalia A. Kuzmina, Venugopalan D. Nair et al. · 2022 · Frontiers in Immunology
49. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages
    Pureum Lee, Chang-Ung Kim, Sang Hwan Seo, Doo‐Jin Kim · 2021 · Immune Network
50. Screening HLA-A-restricted T cell epitopes of SARS-CoV-2 and the induction of CD8+ T cell responses in HLA-A transgenic mice
    Xiaoxiao Jin, Yan Ding, Shihui Sun, Xinyi Wang, Zining Zhou, Xiaotao Kelvin Liu, Miaomiao Li, Xian Chen, Anran Shen, Yandan Wu et al. · 2021 · Cellular and Molecular Immunology
51. Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia
    Laura Marcela Palma Medina, Haris Babačić, Majda Dzidic, Åsa Parke, Marina García, Kimia T. Maleki, Christian Unge, Magda Lourda, Egle Kvedaraite, Puran Chen et al. · 2023 · Respiratory Research
52. What could explain the late emergence of COVID-19 in Africa?
    Rym Lalaoui, Sofiane Bakour, Didier Raoult, Pierre Verger, C. Sokhna, Christian Albert Devaux, Bruno Pradines, Jean‐Marc Rolain · 2020 · New Microbes and New Infections
53. Over 1‐year duration and age difference of SARS‐CoV‐2 antibodies in convalescent COVID‐19 patients
    Fanfan Zeng, Mengjun Wu, Jinbiao Wang, Jianyu Li, Guoyun Hu, Lin Wang · 2021 · Journal of Medical Virology
54. In-depth analysis of human virus-specific CD8+ T cells delineates unique phenotypic signatures for T cell specificity prediction
    Florian Schmidt, Hannah F. Fields, Yovita Ida Purwanti, Ana Milojkovic, Syazwani Salim, Kan Xing Wu, Yannick Simoni, Antonella Vitiello, Daniel T. MacLeod, Alessandra Nardin et al. · 2023 · Cell Reports
55. Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern
    Swayam Prakash, Nisha Rajeswari Dhanushkodi, Latifa Zayou, Izabela Coimbra Ibraim, Afshana Quadiri, Pierre-Gregoire A. Coulon, Delia F. Tifrea, Berfin Suzer, Amin Mohammed Shaik, Amruth Chilukuri et al. · 2024 · Frontiers in Immunology
56. Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology
    Daniele Pala, Marco Pistis · 2021 · Frontiers in Pharmacology
57. A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
    Surapong Koonpaew, Challika Kaewborisuth, Kanjana Srisutthisamphan, Asawin Wanitchang, Theeradej Thaweerattanasinp, Janya Saenboonrueng, Sukontip Poonsuk, Juggragarn Jengarn, Ratchanont Viriyakitkosol, Jarin Kramyu et al. · 2021 · Vaccines
58. Single-cell RNA sequencing reveals immunological rewiring at the maternal-fetal interface following asymptomatic/mild SARS-CoV-2 infection
    Suhas Sureshchandra, Michael Z. Zulu, Brianna M. Doratt, Allen Jankeel, Delia F. Tifrea, Robert A. Edwards, Monica P. Rincon, Nicole Marshall, Ilhem Messaoudi · 2022 · Cell Reports
59. SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
    Αναστασία Παπαδοπούλου, George Karavalakis, Efthymia Papadopoulou, Aliki Xochelli, Zoi Bousiou, Anastasios Vogiatzoglou, Penelope Georgia Papayanni, Aphrodite Georgakopoulou, Maria Giannaki, Fani Stavridou et al. · 2023 · Nature Medicine
60. COVID-19 Immunobiology: Lessons Learned, New Questions Arise
    Aimilios Kaklamanos, Konstantinos Belogiannis, Panagiotis Skendros, Vassilis G. Gorgoulis, Panayiotis G. Vlachoyiannopoulos, Athanasios G. Tzioufas · 2021 · Frontiers in Immunology
61. Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
    A. Aiello, Saeid Najafi-Fard, D. Goletti · 2023 · Frontiers in Immunology
62. SARS-CoV-2 immunity in animal models
    Zhaoming Chen, Yaochang Yuan, Qingtao Hu, Ai-Ru Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yi-Yun He et al. · 2024 · Cellular & Molecular Immunology
63. False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases
    Nastya Kharlamova, Nicky Dunn, Sahl Khalid Bedri, Svante Jerling, Malin Almgren, Francesca Faustini, Iva Gunnarsson, Johan Rönnelid, Rille Pullerits, Inger Gjertsson et al. · 2021 · Frontiers in Immunology
64. Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through ‘reverse phenotyping’
    David S. Fischer, Meshal Ansari, Karolin I. Wagner, Sebastian Jarosch, Yiqi Huang, Christoph H. Mayr, Maximilian Strunz, Niklas Jonathan Lang, Elvira D’Ippolito, Monika Hammel et al. · 2021 · Nature Communications
65. Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity
    Lisa R. Volpatti, Rachel P. Wallace, Shijie Cao, Michal M. Raczy, Ruyi Wang, Laura T. Gray, Aaron T. Alpar, Priscilla S. Briquez, Nikolaos Mitrousis, Tiffany M. Marchell et al. · 2021 · ACS Central Science
66. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV)
    Khadija Khan, Gila Lustig, Mallory P. Bernstein, Derseree Archary, Sandile Cele, Farina Karim, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy et al. · 2021 · Clinical Infectious Diseases
67. Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion
    Tabea M. Eser, Olga Baranov, Manuel Huth, Mohammed I. M. Ahmed, Flora Deák, Kathrin Held, Luming Lin, Kami Pekayvaz, Alexander Leunig, Leo Nicolai et al. · 2023 · Nature Communications
68. Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies
    Kévin Bigaut, Laurent Daniel Kremer, Thibaut Fabacher, Livia Lanotte, Marie‐Céline Fleury, Nicolas Collongues, Jerome De Seze · 2021 · Neurology Neuroimmunology & Neuroinflammation
69. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
    María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, Meiby Rodríguez-González, Laura Rodríguez-Noda, Carmen Valenzuela‐Silva, Beatriz Paredes-Moreno, Belinda Sánchez-Ramírez, Rocmira Pérez-Nicado, Raúl González-Mugica, Tays Hernández-García et al. · 2022 · Vaccine
70. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
    Patricia Almendro-Vázquez, Marta Chivite‐Lacaba, Alberto Utrero‐Rico, Cecilia González‐Cuadrado, Rocío Laguna‐Goya, Miguel Moreno-Batanero, Laura Sánchez-Paz, Joanna Luczkowiak, Nuria Labiod, María Dolores Folgueira et al. · 2022 · Frontiers in Immunology
71. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
    Antonio Pérez‐Martínez, Marta Mora-Rillo, Cristina Ferreras, Pilar Guerra‐García, Bárbara Pascual-Miguel, Carmen Mestre‐Durán, Alberto Manuel Borobia, Antonio J. Carcas, Javier Queiruga‐Parada, Irene Garcia et al. · 2021 · EClinicalMedicine
72. Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine
    Jian Hang Lam, Amit Kumar Khan, Thomas Cornell, Teck Wan Chia, Regine J. Dress, Wen Wang William Yeow, Nur Khairiah Mohd-Ismail, Shrinivas Venkataraman, Kim Tien Ng, Yee‐Joo Tan et al. · 2021 · ACS Nano
73. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination
    Marios Koutsakos, Wen Shi Lee, Adam K Wheatley, Stephen J Kent, Jennifer A. Juno · 2021 · Journal of Leukocyte Biology
74. SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study
    Willem Ashwin Mak, Johannes G.M. Koeleman, Marijke van der Vliet, Frans Keuren, David S. Y. Ong · 2021 · Journal of Infection
75. An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution
    Francisco Javier Gil‐Etayo, Sara Garcinuño, Alberto Utrero‐Rico, Óscar Cabrera-Marante, Daniel Arroyo‐Sánchez, Esther Mancebo, Daniel Enrique Pleguezuelo, Edgard Alfonso Rodriguez-Frias, Luis Miguel Allende, Pablo Morales-Pérez et al. · 2022 · Biomedicines
76. Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective
    Chunlan Zhuang, Xiaohui Liu, Qi Chen, Sun Yuxin, Yingying Su, Shoujie Huang, Ting Wu, Ningshao Xia · 2022 · Frontiers in Microbiology
77. Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review
    Areez Shafqat, Shameel Shafqat, Sulaiman Alsalameh, Junaid Kashir, Khaled Manae AlKattan, Ahmed Yaqinuddin · 2022 · Frontiers in Immunology
78. Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
    Alison Tarke, Yun Zhang, Nils Methot, Tara M. Narowski, Elizabeth Jane Phillips, Simon Alexander Mallal, April Frazier, Gilberto Filaci, Daniela Weiskopf, Jennifer M. Dan et al. · 2023 · Cell Reports Medicine
79. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein
    Lavanya Visvabharathy, Barbara Ann Hanson, Zachary S. Orban, Patrick H. Lim, Nicole M. Palacio, Millenia Jimenez, Jeffrey R. Clark, Edith L. Graham, Eric Michael Liotta, George Tachas et al. · 2023 · Frontiers in Immunology
80. Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID‐19 vaccine: another piece of SARS‐CoV‐2 skin puzzle?
    Carlo Mazzatenta, Vincenzo Piccolo, Gene Pace, Ilaria Jane Romano, Giuseppe Argenziano, Andrea Bassi · 2021 · Journal of the European Academy of Dermatology and Venereology
81. Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership
    David M. Herrington, John W. Sanders, Thomas F. Wierzba, Martha A. Alexander‐Miller, Mark Andrew Espeland, Alain Gerald Bertoni, Allison Mathews, Austin Lyles Seals, Iqra Munawar, Michael S. Runyon et al. · 2021 · BMC Infectious Diseases
82. Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic
    Yutong Wang, Ke Zheng, Wenjing Gao, Jun Lv, Canqing Yu, Lan Wang, Zijun Wang, Bo Wang, Chunxiao Liao, Liming Li · 2022 · Medical Review
83. TNF-α+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies
    Kattria van der Ploeg, Adam S. Kirosingh, Diego AM Mori, Saborni Chakraborty, Zicheng Hu, Benjamín L. Sievers, Karen Blake Jacobson, Hector Fabio Bonilla, Julie Parsonnet, Jason Randolph Andrews et al. · 2022 · Cell Reports Medicine
84. Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals
    Alexandra M. Johansson, Uma Malhotra, Yeseul G. Kim, Rebecca Gomez, Maxwell P. Krist, Anna Wald, David M. Koelle, William W. Kwok · 2021 · PLoS Pathogens
85. (Im)maturity in Tumor Ecosystem
    Keywan Mortezaee, Jamal Majidpoor · 2022 · Frontiers in Oncology
86. Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study
    Maximilian J. Mair, Julia Maria Berger, Manfred Mitterer, Margaretha Gansterer, Arne Cornelius Bathke, Wolfgang Trutschnig, Anna Sophie Berghoff, Thomas Perkmann, Helmuth Haslacher, Wolfgang W. Lamm et al. · 2022 · European Journal of Cancer
87. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
    Chiara Agrati, Concetta Castilletti, Delia Goletti, Alessandra Sacchi, Veronica Bordoni, Davide Mariotti, Stefania Notari, Giulia Matusali, Silvia Meschi, Linda Petrone et al. · 2022 · Scientific Reports
88. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
    Simeng Lin, Louis Ho Shing Lau, Neil Chanchlani, Nicholas Alexander Kennedy, Siew C. Ng · 2022 · Gut
89. Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination
    Vivien Karl, Maike Hofmann, Robert Thimme · 2025 · Journal of Virology
90. Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin
    Claudio Costantini, Frank L. van de Veerdonk, Luigina R. Romani · 2020 · Vaccines
91. Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
    N. Taefehshokr, Sina Taefehshokr, B. Heit · 2020 · Pathogens
92. Prototype multi-biomarker test for point-of-care leprosy diagnostics
    Anouk van Hooij, Elisa M. Tjon Kon Fat, Daniëlle de Jong, Marufa Khatun, Santosh Soren, Abu Sufian Chowdhury, Johan Chandra Roy, Khorshed Alam, Jong-Pill Kim, Jan Hendrik Richardus et al. · 2020 · iScience
93. Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm, Sweden, 2009-2020
    Robert Dyrdak, Emma B. Hodcroft, Martina Wahlund, Richard A. Neher, Jan Albert · 2021 · Journal of Clinical Virology
94. Serum IgG levels in children 6 months after SARS-CoV-2 infection and comparison with adults
    Silvia Bloise, Alessia Marcellino, Alessia Testa, Anna Dilillo, Saverio Mallardo, Sara Isoldi, Vanessa Martucci, Maria Teresa Sanseviero, Emanuela Del Giudice, Donatella Iorfida et al. · 2021 · European Journal of Pediatrics
95. Development of Humoral and Cellular Immunological Memory Against SARS-CoV-2 Despite B-Cell Depleting Treatment in Multiple Sclerosis
    Klara Asplund Högelin, Nicolas Ruffin, Elisa Pin, Anna Månberg, Sophia Hober, Guro Gafvelin, Hans Grönlund, Peter Nilsson, Mohsen Khademi, Tomas P Olsson et al. · 2021 · iScience
96. The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA-supertype-dependent manner
    David J. Hamelin, Dominique Fournelle, Jean‐Christophe Grenier, Jana Schockaert, Kevin A. Kovalchik, Peter Kubiniok, Fatima Mostefai, Jérôme D. Duquette, Frederic Saab, Isabelle Sirois et al. · 2021 · Cell Systems
97. Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination
    Marta Fernández‐González, Vanesa Agulló, Sergio Padilla, José Alberto García, Javier García‐Abellán, Ángela Botella, Paula Mascarell, Montserrat Ruiz‐García, Mar Masiá, Félix Gutiérrez · 2021 · Clinical Infectious Diseases
98. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
    Keywan Mortezaee, Jamal Majidpoor · 2022 · Frontiers in Immunology
99. The unique presentation of SARS-CoV-2 Infection in patients with B-cell depletion: definition of ‘persistent inflammatory sero-negative COVID’
    Ana Belkin, Avshalom Leibowitz, Liat Shargian, Dafna Yahav · 2022 · Clinical Microbiology and Infection
100. Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19
     J. Garmendia, A. García, C. D. De Sanctis, M. Hajdůch, J. D. de Sanctis · 2022 · Current Issues in Molecular Biology